Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Novartis

NYSE:NVSPharma

Basel, Switzerland · Est. 1996 · 78,000 employees

Global healthcare company focused on innovative medicines across multiple therapeutic areas.

101

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

130

Indications↗

Distinct diseases across all programs

3,728

Clinical Trials↗

All sponsored trials (all statuses)

312

Orange Book Patents

Across 33 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

101 drugs in development

Approved3

Phase 328

Phase 235

Phase 128

Preclinical34

By Therapeutic Area

top 6

Oncology

4735%

Neurology

129%

Cardiovascular

86%

Nephrology

75%

Immunology

75%

Hematology

65%

R&D Momentum

100/100

Pipeline Velocity

91/100

Trial Completion Rate

84/100

Pipeline Concentration

18/100

Pipeline Freshness

72/100

Strategic Signals

↗Active in Ophthalmology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Study Assessing the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

A Phase 1b, Open Label, 2-Part Study to Evaluate the Effect of Pelabresib (DAK539/CPI-0610) on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Patients With Advanced Malignancies

A Phase 3, Randomized, Double-blind, Active-control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients With Myelofibrosis Who Are JAK Inhibitor Naive

TulmiSTAR-01: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

A Phase IIIb Study to Characterize the Efficacy and Safety of Adjuvant Ribociclib Plus Endocrine Therapy in a Close-to-clinical Practice Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)

Active, not recruiting

A Post-trial Access Roll-over Study to Allow Access to Ribociclib (LEE011) for Patients Who Are on Ribociclib Treatment in Novartis-sponsored Study

An Open-label, Multi-center, Phase I/II Study of GVV858 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer and Other Advanced Solid Tumors

Active, not recruiting

A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)

An Open-label, Multi-center, Phase I/Ib Study of IEV407 as a Single Agent and in Combination With Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2- Negative Breast Cancer

Active, not recruiting

A Phase II, Randomized, Open-label, Multi-center Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Active, not recruiting

KontRASt-R: An Open-label, Multi-center, Rollover Study for Participants Who Have Been Previously Enrolled Into a Novartis-sponsored Opnurasib (JDQ443) Study and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study

Details

Company Info

Company Overview

$230.0B

Mkt Cap

$50.3B

Revenue

$13.2B

Cash

CEOVas Narasimhan

Founded1996

Employees78,000

HQBasel, Switzerland

ExchangeNYSE:NVS

Websitenovartis.com

LinkedInCompany Page

Therapeutic Focus

MusculoskeletalNephrologyMetabolic & EndocrineHematologyNeurologyOphthalmologyCardiovascularOncologyOtherInfectious DiseasePsychiatryImmunologyDermatologyRare DiseaseGastroenterologyRespiratory

Patent Expirations

116 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Promacta KitJul 13, 2025 AfinitorNov 1, 2025 Promacta KitJan 13, 2026 Neoral5 patentsJan 27, 2026 ZykadiaApr 25, 2026 AfinitorMay 1, 2026 Voltaren4 patentsJun 16, 2026 RitalinMar 15, 2027

108 more

Voltaren12 patentsMar 22, 2027 Trileptal11 patentsApr 13, 2027 Leqvio2 patentsMay 10, 2027 Mekinist2 patentsMay 28, 2027 Promacta Kit5 patentsAug 1, 2027 Travatan2 patentsSep 20, 2027 NeoralNov 3, 2027 Tabrecta2 patentsNov 19, 2027 Zykadia2 patentsNov 20, 2027 GilenyaDec 25, 2027 Promacta Kit5 patentsFeb 1, 2028 VoltarenApr 21, 2028 ZykadiaApr 29, 2028 AfinitorJul 1, 2028 Pluvicto2 patentsAug 14, 2028 VanrafiaAug 22, 2028 MayzentAug 27, 2028 RydaptOct 9, 2028 OnbrezOct 11, 2028 Tegretol2 patentsNov 10, 2028 LeqvioDec 4, 2028 KisqaliDec 17, 2028 Voltaren12 patentsFeb 24, 2029 TegretolMar 13, 2029 Travatan5 patentsMar 13, 2029 Tafinlar2 patentsMay 4, 2029 TabrectaMay 20, 2029 NeoralJun 2, 2029 Alphagan4 patentsJul 27, 2029 Kisqali2 patentsAug 20, 2029 PiqraySep 10, 2029 TykerbSep 18, 2029 ZofranNov 23, 2029 Tafinlar5 patentsJan 20, 2030 Kisqali4 patentsFeb 20, 2030 Voltaren8 patentsApr 23, 2030 Travatan3 patentsJun 18, 2030 ZykadiaJun 29, 2030 ZofranJul 13, 2030 Alphagan2 patentsJul 14, 2030 MekinistOct 14, 2030 MayzentNov 30, 2030 RydaptDec 2, 2030 NeoralDec 13, 2030 TravatanFeb 14, 2031 Ritalin6 patentsFeb 15, 2031 NeoralFeb 25, 2031 Alphagan7 patentsMar 25, 2031 Tafinlar2 patentsApr 15, 2031 TabrectaJun 5, 2031 Kisqali3 patentsSep 13, 2031 MayzentJan 5, 2032 Zykadia2 patentsJan 18, 2032 Mekinist8 patentsJan 27, 2032 VanrafiaFeb 18, 2032 Ritalin18 patentsMar 23, 2032 Gilenya2 patentsMar 30, 2032 NeoralApr 16, 2032 Kisqali2 patentsMay 9, 2032 Pataday Once Daily Relief2 patentsMay 19, 2032 TabrectaNov 19, 2032 TegretolFeb 27, 2033 PiqrayApr 29, 2033 Ritalin8 patentsAug 14, 2033 Neoral3 patentsAug 23, 2033 TafinlarAug 30, 2033 Neoral2 patentsFeb 7, 2034 TafinlarFeb 28, 2034 Vanrafia2 patentsJul 7, 2034 Fabhalta2 patentsJul 14, 2034 Kisqali2 patentsAug 7, 2034 Leqvio2 patentsAug 18, 2034 Rhapsido2 patentsNov 13, 2034 ExjadeNov 21, 2034 Kisqali2 patentsFeb 7, 2035 Tabrecta2 patentsJul 22, 2035 ScemblixOct 29, 2035 Ritalin11 patentsOct 30, 2035 PluvictoNov 11, 2035 PluvictoMar 22, 2036 Kisqali5 patentsApr 14, 2036 Mayzent2 patentsApr 23, 2036 LeqvioAug 25, 2036 NeoralSep 29, 2036 Ritalin5 patentsFeb 3, 2037 Piqray2 patentsFeb 17, 2037 Neoral3 patentsFeb 28, 2037 Lioresal2 patentsSep 8, 2037 ZykadiaDec 13, 2037 Ritalin2 patentsJan 25, 2038 Tafinlar2 patentsJun 29, 2038 Fabhalta2 patentsAug 30, 2038 NeoralNov 20, 2038 Cysteine Hydrochloride20 patentsJan 15, 2039 Klor-ConMar 7, 2039 Lioresal4 patentsJul 29, 2039 NeoralOct 11, 2039 TegretolJan 31, 2040 GleevecApr 27, 2040 Scemblix3 patentsMay 14, 2040 Vanrafia4 patentsDec 16, 2040 VanrafiaFeb 23, 2041 Fabhalta4 patentsMay 17, 2041 PluvictoSep 17, 2041 Lioresal2 patentsSep 29, 2041 NeoralApr 1, 2042 RhapsidoJan 20, 2043 VanrafiaMar 25, 2043

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(8 drugs)

5

—

3

2

1

Cardiovascular(8 drugs)

Dermatology(6 drugs)

—

—

4

2

—

Dermatology(6 drugs)

Gastroenterology(1 drug)

—

—

—

—

1

Gastroenterology(1 drug)

Hematology(6 drugs)

1

1

1

3

2

Hematology(6 drugs)

Immunology(7 drugs)

2

1

4

1

—

Immunology(7 drugs)

Infectious Disease(4 drugs)

—

—

4

—

—

Infectious Disease(4 drugs)

Metabolic & Endocrine(1 drug)

1

—

—

—

—

Metabolic & Endocrine(1 drug)

Nephrology(7 drugs)

—

2

2

5

1

Nephrology(7 drugs)

Neurology(12 drugs)

2

1

4

7

—

Neurology(12 drugs)

Oncology(47 drugs)

23

19

10

6

—

Oncology(47 drugs)

Ophthalmology(2 drugs)

1

—

1

—

1

Ophthalmology(2 drugs)

Psychiatry(1 drug)

—

—

1

—

—

Psychiatry(1 drug)

Rare Disease(5 drugs)

—

—

—

5

—

Rare Disease(5 drugs)

Respiratory(4 drugs)

—

—

3

1

—

Respiratory(4 drugs)

Unknown / Other(22 drugs)

3

7

6

7

1

Unknown / Other(22 drugs)

Regulatory

Regulatory Timeline

20252 events

FDANov 25

Klor-Con — POKONZA

Application NDA206814 (NDA)

FDASep 30

Rhapsido — RHAPSIDO

Application NDA218436 (NDA)

202618 events

FDAAug 19

Leqvio — LEQVIO

Application NDA214012

FDAJul 16

Fabhalta — FABHALTA

Application NDA218276

FDAJun 1

Afinitor — AFINITOR DISPERZ

Application NDA203985

FDAJun 1

Afinitor — AFINITOR

Application NDA022334

FDAMay 7

Mekinist — MEKINIST

Application NDA204114

FDAApr 17

Cosentyx — COSENTYX

Application BLA125504

FDAApr 17

Cosentyx — COSENTYX

Application BLA761349

FDAApr 17

Cosentyx — COSENTYX

Application BLA125504

FDAApr 17

Cosentyx — COSENTYX

Application BLA761349

FDAApr 1

Kesimpta — KESIMPTA, ARZERRA

Application BLA125326

FDAMar 26

Mekinist — MEKINIST

Application NDA217513

FDAMar 26

Mekinist — MEKINIST

Application NDA204114

FDAMar 26

Tafinlar — TAFINLAR

Application NDA217514

FDAMar 26

Tafinlar — TAFINLAR

Application NDA202806

FDAMar 12

Cosentyx — COSENTYX

Application BLA125504

FDAMar 12

Cosentyx — COSENTYX

Application BLA761349

FDAFeb 12

Leqvio — LEQVIO

Application NDA214012

FDAFeb 12

Leqvio — LEQVIO

Application NDA214012

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)